Lecanemab
Sponsors
Eisai Limited, Washington University School Of Medicine, Washington University School of Medicine, Eisai Inc., Ali Rezai
Conditions
Alzheimer DiseaseAlzheimer Disease 1Alzheimer's DiseaseAlzheimer's Disease, FamilialAlzheimers DiseaseAlzheimers Disease, FamilialDementiaDominantly Inherited Alzheimer Disease (DIAD)
Early Phase 1
Phase 1
A Study of Subcutaneous Lecanemab in Healthy Participants
CompletedNCT05045716
Start: 2021-09-07End: 2021-12-07Updated: 2022-01-19
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
CompletedNCT05533801
Start: 2022-09-06End: 2023-01-06Updated: 2023-01-18
Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Active, not recruitingNCT01760005
Start: 2012-12-01End: 2028-07-01Target: 490Updated: 2026-02-13
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Active, not recruitingNCT05269394
Start: 2021-12-22End: 2028-07-01Updated: 2026-02-13
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD)
Active, not recruitingCTIS2024-515198-91-00
Start: 2022-12-20Target: 24Updated: 2025-07-04
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Active, not recruitingNCT06602258
Start: 2024-09-30End: 2027-08-18Updated: 2026-02-11
Phase 3
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Active, not recruitingNCT04468659
Start: 2020-07-14End: 2031-01-16Target: 1400Updated: 2026-03-13
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Active, not recruitingNCT06384573
Start: 2024-06-10End: 2030-06-01Updated: 2026-03-05
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study with an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)
Active, not recruitingCTIS2024-510888-39-00
Start: 2021-07-21Target: 20Updated: 2025-08-27
A Placebo-Controlled, Double-Blind, Parallel-Group, 18 Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
Active, not recruitingCTIS2024-510887-22-00
Start: 2019-09-30Target: 348Updated: 2025-11-17
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
RecruitingNCT06530732
Start: 2024-07-01End: 2026-09-30Target: 60Updated: 2025-01-16
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer’s Disease
CompletedCTIS2024-513458-31-00
End: 2025-05-02Target: 4Updated: 2024-12-17